Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (GB:0QAV)
:0QAV
0QAV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.68 - €6.90
Previous CloseN/A
Volume19.00
Average Volume (3M)941.00
Market Cap
€152.85M
Enterprise ValueN/A
Total Cash (Recent Filing)€36.20M
Total Debt (Recent Filing)€20.52M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 14, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding47,133,327
10 Day Avg. Volume1,299
30 Day Avg. Volume941
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)46.47
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.00Price Target Upside291.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsPreliminary survival data demonstrated favorable results compared to historical controls for patients treated with NBTXR3.
Partnership And Cost ManagementThe company’s partner is expected to bear the cost of running the NANORAY-312 study and complete development and initiate commercialization of NBTXR3.
Bears Say
Financial And Partnership RisksThere are risks associated with clinical, commercial, financial, partnership, and intellectual property aspects.
Financial Trade-OffsThe main trade-off is a $105m reduction in potential future payments, however, the core value-driving milestones remain intact.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.80% Public Companies and
Individual Investors
0QAV FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest share price was €2.68 and its highest was €6.89 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €152.85M.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is May 14, 2025 which is in 41 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.51.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 47,133,327 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in GB:0QAV
---
Company Description
Nanobiotix SA
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
---
0QAV Stock 12 Month Forecast
Average Price Target
€13.00
▲(291.57% Upside)
Technical Analysis
Best Analysts Covering 0QAV
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
+19.04%
reiterated a buy rating 4 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +19.04% per trade.
---